Literature DB >> 11703031

In vitro efficacy of chemotherapeutics as determined by 50% inhibitory concentrations in cell cultures of mammary gland tumors obtained from dogs.

D Simon1, J W Knebel, W Baumgartner, M Aufderheide, A Meyer-Lindenberg, I Nolte.   

Abstract

OBJECTIVE: To determine the 50% inhibitory concentration (IC-50) of carboplatin, cisplatin, and doxorubicin in cell cultures of mammary gland tumors obtained from dogs and to assess whether in vitro efficacy was within the range of clinically relevant concentrations, SAMPLE POPULATION: 30 mammary gland tumors excised from dogs. PROCEDURE: Cell cultures were established from the 30 tumors. Cultures then were treated with carboplatin, cisplatin, or doxorubicin. Growth inhibition of cultures was assessed via DNA measurement 24, 48, and 72 hours after treatment. The IC-50 values were calculated by use of linear interpolation.
RESULTS: Cultures varied in their pattern of susceptibility. Doxorubicin induced significantly lower IC-50 values than the platinum derivatives. Cisplatin and carboplatin had comparable effects. The IC-50 values for carboplatin and doxorubicin were in the range of clinically relevant concentrations, but only part of the cisplatin cultures had IC-50 values within clinically relevant concentrations. We did not detect differences in the in vitro susceptibility among subtypes of tumors (ie, adenocarcinoma, solid carcinoma, malignant mixed tumor). CONCLUSION AND CLINICAL RELEVANCE: The IC-50 values determined in this study allowed assessment of in vitro drug efficacy of chemotherapeutics in cultures of mammary gland tumors obtained from dogs. Variations in susceptibility were evident and emphasize the importance of assessing susceptibility and resistance patterns for each tumor. Prospective studies to assess direct correlations between in vitro and in vivo efficacy must be performed to determine the clinical predictive value of this in vitro chemosensitivity assay for treatment of dogs with mammary gland tumors.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11703031     DOI: 10.2460/ajvr.2001.62.1825

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  10 in total

1.  Evidence for heterogeneity in response to treatment in mammary tumors of dogs as happens in humans.

Authors:  Ozge Turna; Ayca Uvez; Aslihan Baykal; Elif Sedef Develi; Murat Diramali; Kivilcim Sonmez; Didem Karakas; Guven Kasikci; Elif Ilkay Armutak; Engin Ulukaya
Journal:  Vet Res Commun       Date:  2022-05-16       Impact factor: 2.459

2.  Three-dimensional hydrogel culture systems support growth and determination of chemosensitivity of feline sarcoma and carcinoma cell lines.

Authors:  Jacqueline V J Cavalcanti; Kimberly A Selting; Mai T Ngo; Christine K Tran Hoang; David J Schaeffer; Timothy M Fan; Brendan A C Harley; Heidi Phillips
Journal:  Am J Vet Res       Date:  2022-05-14       Impact factor: 1.055

3.  Dichloroacetate affects proliferation but not apoptosis in canine mammary cell lines.

Authors:  Tatjana P Harting; Mandy Stubbendorff; Susanne C Hammer; Patrik Schadzek; Anaclet Ngezahayo; Hugo Murua Escobar; Ingo Nolte
Journal:  PLoS One       Date:  2017-06-07       Impact factor: 3.240

4.  Disaccharides obtained from carrageenans as potential antitumor agents.

Authors:  Gustavo H Calvo; Vanina A Cosenza; Daniel A Sáenz; Diego A Navarro; Carlos A Stortz; Mariela A Céspedes; Leandro A Mamone; Adriana G Casas; Gabriela M Di Venosa
Journal:  Sci Rep       Date:  2019-04-30       Impact factor: 4.379

5.  Tumor slices as a model to evaluate doxorubicin in vitro treatment and expression of trios of genes PRSS11, MTSS1, CLPTM1 and PRSS11, MTSS1, SMYD2 in canine mammary gland cancer.

Authors:  Renata A Sobral; Suzana T Honda; Maria Lucia H Katayama; Helena Brentani; M Mitzi Brentani; Diogo F C Patrão; Maria Aparecida A K Folgueira
Journal:  Acta Vet Scand       Date:  2008-07-04       Impact factor: 1.695

6.  Human Genetic Relevance and Potent Antitumor Activity of Heat Shock Protein 90 Inhibition in Canine Lung Adenocarcinoma Cell Lines.

Authors:  Francisco Clemente-Vicario; Carlos E Alvarez; Jennie L Rowell; Satavisha Roy; Cheryl A London; William C Kisseberth; Gwendolen Lorch
Journal:  PLoS One       Date:  2015-11-11       Impact factor: 3.240

7.  Synergistic growth inhibitory effect of deracoxib with doxorubicin against a canine mammary tumor cell line, CMT-U27.

Authors:  Tülay Bakirel; Fulya Üstün Alkan; Oya Üstüner; Suzan Çinar; Funda Yildirim; Gaye Erten; Utku Bakirel
Journal:  J Vet Med Sci       Date:  2016-01-29       Impact factor: 1.267

8.  BB-Cl-Amidine as a novel therapeutic for canine and feline mammary cancer via activation of the endoplasmic reticulum stress pathway.

Authors:  Melissa M Ledet; Robyn Anderson; Rebecca Harman; Aaron Muth; Paul R Thompson; Scott A Coonrod; Gerlinde R Van de Walle
Journal:  BMC Cancer       Date:  2018-04-12       Impact factor: 4.430

9.  Pharmacokinetics and toxicity of subcutaneous administration of carboplatin in poloxamer 407 in a rodent model pilot study.

Authors:  Marije Risselada; Keith E Linder; Emily Griffith; Brittney V Roberts; Gigi Davidson; William C Zamboni; Kristen M Messenger
Journal:  PLoS One       Date:  2017-10-05       Impact factor: 3.240

10.  Evaluation of bioabsorbable calcium sulfate hemihydrate beads for local delivery of carboplatin.

Authors:  Marine Traverson; Connor E Stewart; Mark G Papich
Journal:  PLoS One       Date:  2020-11-05       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.